Last reviewed · How we verify
Ypeginterferon alfa-2b
Ypeginterferon alfa-2b is a recombinant form of interferon alfa-2b used to modulate the immune system.
Ypeginterferon alfa-2b is a recombinant form of interferon alfa-2b used to modulate the immune system. Used for Treatment of chronic hepatitis B, Treatment of chronic hepatitis C.
At a glance
| Generic name | Ypeginterferon alfa-2b |
|---|---|
| Also known as | Peginterferon alfa-2b, peginterferon alfa-2b |
| Sponsor | Xiamen Amoytop Biotech Co., Ltd. |
| Drug class | Interferon |
| Target | Interferon receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology, Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
It works by enhancing the body's natural immune response to fight viral infections and cancer cells. Interferons are proteins that are naturally produced by the body to fight off viral infections, and Ypeginterferon alfa-2b is a synthetic version of one of these proteins. By stimulating the immune system, it can help to reduce the severity of symptoms and slow down the progression of diseases.
Approved indications
- Treatment of chronic hepatitis B
- Treatment of chronic hepatitis C
Common side effects
- Flu-like symptoms
- Fatigue
- Headache
- Myalgia
- Nausea
Key clinical trials
- A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B (PHASE2)
- Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B (PHASE3)
- Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients (PHASE3)
- Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B (PHASE2)
- Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |